Prot #D3250C00017:A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients with Uncon

    Project: Research project

    Project Details

    StatusFinished
    Effective start/end date1/15/151/15/18

    Funding

    • AstraZeneca Pharmaceuticals LP (Prot #D3250C00017)